Journal of Oncology / 2020 / Article / Tab 6

Research Article

Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 6

Chemotherapy regimens that were administered as second-line treatment.

 Second-line chemotherapy regimenN%

Nab-paclitaxel/gemcitabine3632.1
FOLFIRINOX2724.1
CAPOXIRI10.9
FOLFOX1816.1
CAPOX43.6
Gemcitabine65.4
Capecitabine21.8
FOLFIRI65.4
Gemcitabine/oxaliplatin65.4
Gemcitabine/capecitabine21.8
Cisplatin/gemcitabine10.9
Cisplatin/irinotecan10.9
Nab-paclitaxel21.8
Total112100.0

CAPOX, oxaliplatin/capecitabine; CAPOXIRI, oxaliplatin/irinotecan/capecitabine; FOLFIRI, irinotecan/leucovorin/5-fluorouracil; FOLFOX, oxaliplatin/leucovorin/5-fluorouracil; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.